Nontoxic Cobalt(III) Schiff Base Complexes with Broad-Spectrum Antifungal Activity

被引:44
作者
Frei, Angelo [1 ]
King, A. Paden [2 ]
Lowe, Gabrielle J. [1 ]
Cain, Amy K. [3 ]
Short, Francesca L. [3 ]
Dinh, Hue [3 ,4 ]
Elliott, Alysha G. [1 ]
Zuegg, Johannes [1 ]
Wilson, Justin J. [2 ]
Blaskovich, Mark A. T. [1 ]
机构
[1] Univ Queensland, Ctr Superbug Solut, Inst Mol Biosci, St Lucia, Qld 4072, Australia
[2] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA
[3] Macquarie Univ, Dept Mol Sci, Sydney, NSW 2109, Australia
[4] Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia
基金
英国惠康基金; 瑞士国家科学基金会; 澳大利亚研究理事会; 美国国家卫生研究院;
关键词
antifungal agents; cobalt; metallodrugs; Schiff base complexes; CRYPTOCOCCAL MENINGITIS; GALLERIA-MELLONELLA; METAL-COMPLEXES; GLOBAL BURDEN; AGENTS; INSIGHTS;
D O I
10.1002/chem.202003545
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Resistance to currently available antifungal drugs has quietly been on the rise but overshadowed by the alarming spread of antibacterial resistance. There is a striking lack of attention to the threat of drug-resistant fungal infections, with only a handful of new drugs currently in development. Given that metal complexes have proven to be useful new chemotypes in the fight against diseases such as cancer, malaria, and bacterial infections, it is reasonable to explore their possible utility in treating fungal infections. Herein we report a series of cobalt(III) Schiff base complexes with broad-spectrum antifungal activity. Some of these complexes show minimum inhibitory concentrations (MIC) in the low micro- to nanomolar range against a series of Candida and Cryptococcus yeasts. Additionally, we demonstrate that these compounds show no cytotoxicity against both bacterial and human cells. Finally, we report the first in vivo toxicity data on these compounds in Galleria mellonella, showing that doses as high as 266 mg kg(-1) are tolerated without adverse effects, paving the way for further in vivo studies of these complexes.
引用
收藏
页码:2021 / 2029
页数:9
相关论文
共 44 条
  • [1] [Anonymous], 2020, BOLD THERAPEUTICS
  • [2] [Anonymous], 2018, CDC FACT SHEET
  • [3] Drugs in Development for Malaria
    Ashley, Elizabeth A.
    Phyo, Aung Pyae
    [J]. DRUGS, 2018, 78 (09) : 861 - 879
  • [4] THE ANTIMALARIAL FERROQUINE: FROM BENCH TO CLINIC
    Biot, C.
    Nosten, F.
    Fraisse, L.
    Ter-Minassian, D.
    Khalife, J.
    Dive, D.
    [J]. PARASITE, 2011, 18 (03) : 207 - 214
  • [5] Classification of Metal-Based Drugs according to Their Mechanisms of Action
    Boros, Eszter
    Dyson, Paul J.
    Gasser, Gilles
    [J]. CHEM, 2020, 6 (01): : 41 - 60
  • [6] Spectroscopy and electrochemistry of cobalt(III) Schiff base complexes
    Bottcher, A
    Takeuchi, T
    Hardcastle, KI
    Meade, TJ
    Gray, HB
    Cwikel, D
    Kapon, M
    Dori, Z
    [J]. INORGANIC CHEMISTRY, 1997, 36 (12) : 2498 - 2504
  • [7] Multidrug-resistant Candida auris: an epidemiological review
    Chakrabarti, Arunaloke
    Singh, Shreya
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (06) : 551 - 562
  • [8] Biguanide Iridium(III) Complexes with Potent Antimicrobial Activity
    Chen, Feng
    Moat, John
    McFeely, Daniel
    Clarkson, Guy
    Hands-Portman, Ian J.
    Furner-Pardoe, Jessica P.
    Harrison, Freya
    Dowson, Christopher G.
    Sadler, Peter J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (16) : 7330 - 7344
  • [9] Chemical redox agents for organometallic chemistry
    Connelly, NG
    Geiger, WE
    [J]. CHEMICAL REVIEWS, 1996, 96 (02) : 877 - 910
  • [10] Developing Galleria mellonella as a model host for human pathogens
    Cook, Simon M.
    McArthur, Jason D.
    [J]. VIRULENCE, 2013, 4 (05) : 350 - 353